Adenosine Vials Rx
Generic Name and Formulations:
Adenosine 3mg/mL; soln for IV infusion; preservative-free.
Various generic manufacturers
Indications for Adenosine Vials:
Adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to undergo adequate exercise stress.
Give peripherally as a continuous IV infusion. ≥18yrs: 140mcg/kg/min over 6 mins for a total dose of 0.84mg/kg. Infusion rate (mL/min)= 0.140 (mg/kg/min) x total body weight (kg)/adenosine conc. (3mg/mL). See full labeling.
<18yrs: not established.
2nd- or 3rd-degree AV block or sinus node disease (eg, sick sinus syndrome, symptomatic bradycardia), unless paced. Bronchoconstructive or bronchospastic disease (eg, asthma).
Have resuscitative measures available. Increased risk of cardiovascular events in patients with acute MI, unstable angina, or cardiovascular instability; avoid use. Pre-existing 1st-degree AV block or bundle branch block. Discontinue if persistent or symptomatic high-grade AV block or hypotension occurs. Autonomic dysfunction. Stenotic valvular heart disease. Pericarditis or pericardial effusions. Stenotic carotid artery disease with cerebrovascular insufficiency. Hypovolemia. Obstructive lung disease (eg, emphysema, bronchitis). Discontinue if severe respiratory difficulties occur. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by β-blockers, cardiac glycosides, calcium channel blockers; use caution. Increased risk of seizures with concomitant methylxanthines (eg, caffeine, aminophylline, theophylline): not recommended. Potentiated by dipyridamole.
Flushing, chest discomfort, dyspnea, headache, throat/neck/jaw discomfort, GI discomfort, lightheadedness/dizziness; cardiac arrest, sustained ventricular tachycardia, MI, bronchoconstriction, hypo- or hypertension, cerebrovascular accident, convulsive seizures, atrial fibrillation.
Formerly known under the brand name Adenoscan.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities